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Surlrlmary 
Fas  (CD95)  and  its  ligand  are  central  regulatory molecules in  hematopoietic  cells.  Previous 
studies have suggested a role for Fas in the regulation of tumor progression, but Fas has not yet 
been conclusively identified as a tumor suppressor. Fas-deficient individuals lack mahgnant tu- 
mors, perhaps because of regulation by T  cells. To investigate such a possibility, mice deficient 
in both T  cells and Fas were generated, and they were found to develop severe B cell dysregu- 
lotion  characterized by malignant,  lethal B  cell lymphoma. Lymphoma arose from a  mono- 
clonal B220+CD19-CD5-CD23 -  B  cell secreting immunoglobulin M,  K rheumatoid factor. 
In contrast, animals containing ~x]3 T  cells, y8 T  cells, and/or functional Fas suppressed the de- 
velopment of lymphoma. These  data  indicate  that  Fas  functions  as  a  tumor suppressor,  and 
identifies roles for both or]3 T  cells and y8 T  cells in Fas-independent tumor regulation. 
C 
entral  regulators  of  immune  responses  include  Fas 
(CD95)  and its ligand. Activated lymphocytes upreg- 
ulate  Fas,  rendering  themselves  susceptible  to  apoptosis 
upon interaction with  ceils  expressing Fas ligand  (1).  The 
central importance of these molecules is illustrated by Fas- 
deficient mice and humans, who have defective peripheral 
lymphocyte tolerance because of an inability to  complete 
activation-induced cell death (2-5). These regulatory inter- 
actions may involve both T  and B cells (6, 7). 
Such findings suggest that Fas deficiency promotes lym- 
phoid  tumor  development.  Indeed,  a  regulatory  role  for 
Fas in tumor progression has been suggested by its altered 
expression on some human cancers (8),  and the allelic loss 
of chromosome 10@3,  to which Fas maps (9),  in prostate 
(10),  brain (11),. skin (12),  endometrial (13),  and lymphoid 
(14)  malignancies.  Defects in  Fas  alone,  however,  do  not 
induce  malignancy,  causing instead  a  nonmalignant  lym- 
phoproliferation ofCD3+CD4-CD8 -  T  cells in both mice 
and humans (3,  15,  16).  While B  cell "tumors" have been 
described in Fas-deficient Ipr mice on the SJL background, 
which  itself develops B  cell hyperplasias, these  polyclonal 
populations resemble mature t3 cells and are not malignant 
(17).  Instead, the absence of functional Fas promotes patho- 
logical B  cell  hyperactivity resulting  in  T  cell-dependent 
autoantibody production and systemic autoimmune disease 
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(18).  Thus, while Fas deficiency clearly causes lymphocyte 
dysregulation, it alone does not result in malignant transfor- 
mation. 
As  one  explanation  of these  findings,  Fas-deficient tu- 
mors in situ may be regulated by T  cells, which have previ- 
ously been shown to reject experimental tumors  (19).  To 
test this hypothesis,  T  cell-deficient Ipr mice were  devel- 
oped  and  observed.  Such  mice  spontaneously developed 
intraabdominal B cell lymphoma with significant associated 
mortality. In contrast, animals possessing et]3 T  cells,  ",/8 T 
cells, and/or functional Fas suppressed lymphoma develop- 
ment. Thus, Fas functions as a tumor suppressor, and both 
ot[3 and ~/8 T  cells regulate lymphoma progression. 
Materials and Methods 
Mice.  T  cell-deficient  Ipr animals  were  obtained  by inter- 
crossing  the  FI  offspring  of TCR 13 -/- TCR B  -/-  C57BL/6 
and  MRL/Ipr  mice  (both  from  the Jackson  Laboratory,  Bar 
Harbor, ME).  Mice were screened for the TCR-13 genotype by 
PCR on tail DNA using primers TCRJB12F  (5'-CTCATGTCT- 
GGGACTACATTCTAATGAGGC), TCRJB13R  (S'-ACCTA- 
CAACAATGAGCCGGCTTCCTTCTCC),  and  NEO1471Fl:k 
(5'-ACGGTATCGCCGCTCCCGATTCGCAGC). The  TCR- 
JB12F-TCRJB13R  combination  yielded  a  241-bp  fragment 
corresponding  to  the  wild-type  locus,  while  the  TCRJB12F- 
NEO1471FP,  combination  yielded  a  550-bp  fragment  corre- 
sponding to the targeted 13 locus. TCR-g genotype was screened 
by Southern  analysis of EcoRN-digested tail DNA, using a 700- 
bp probe isolated from the TCt/.-g locus between Cgl and Vg5 
(Hayday, A.C., unpubhshed  data), which detected both wild-type 
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mined by PCR as described previously (20).  All mice, homozy- 
gotic  at all three loci, were  raised under specific pathogen-free 
conditions at the Yale University School of Medicine. 
Pathology.  Lethal lymphoma was  diagnosed by the  develop- 
ment of malignant ascites  and associated death, along with histo- 
pathological evidence for lymphoma at autopsy  (Figs.  1  and 2). 
Formalin-fixed tissue  was  embedded  in paraffin,  sectioned,  and 
stained with hematoxylin and eosin via standard protocol by the 
Department of Pathology, Yale University School of Medicine. 
For immunofluorescent studies, tissues were frozen in OCT em- 
bedding medium (Miles Inc., Elkhart, IN) at -80~  4-b~M sec- 
tions were dried in room air for 30 min, washed three times in 
PBS for 5 min, fixed in ethyl ether/ethanol (50% vol/vol) for 10 
rain, washed in 95% ethanol for 20 rain, and washed three times 
in PBS  for  5  min.  Fluorescein-conjugated antibodies were  ap- 
plied at a concentration of 25 Izg/ml in PBS for 45 rain in a hu- 
midified chamber.  Sections were  then washed  twice with PBS, 
mounted with Permount (Fisher Scientific, Springfield, NJ), and 
visualized by  an Axioskop  fluorescent  microscopy  (Carl  Zeiss, 
Inc.,  Thornwood,  NY).  Antibodies included FITC-conjugated 
145-2Cll  (anti-CD3), H129.19  (anti-CD4), 53-7.3  (anti-CD5), 
53-6.7 (anti-CD8ci), 1D3 (anti-CD19), B3B4 (anti-CD23), 1M7 
(anti-CD44), 16A (anti-CD45RB), RA3-6B2 (anti-B220), 36-7-5 
(anti-H-2Kk), AF6-88.5  (anti-H-2Kb), MEL-14  (anti-CD62L), 
A1  (anti-Ly49A), 5E6 (anti-Ly49C), PK136 (anti-NKl.1), H57- 
597 (anti-TCR-C[3; all from Pharmingen, San Diego, CA), poly- 
clonal goat anti-mouse IglVl and polyclonal goat anti-mouse IgG 
(Sigma Chemical Co., St.  Louis, MO), and polyclonal goat anti- 
mouse IgD (Southern Biotechnology Associates, Birmingham, AL). 
V(D)J Sequencing.  Genomic DNA was isolated from whole tis- 
sue by proteinase K/phenol extraction. PCR was performed with 
AmpliTaq  ~ in a  GeneAmp 9600  (Perkin-Elmer Corp.,  Norwalk, 
CT) at 94~  30 s; 60~  1 rain; 72~  1 rain for 35 cycles.  For- 
ward  primers  included  VH7183F  (5'-GAAGTGAAGCTGGT- 
GGAGTCTGGGGGAG)  and  VHJ558F  (5'-GAGGTCCAG- 
CTGCAGCAGTCTGGACCTG); reverse  primers includedJH4R 
(5'-CTGAGGAGACGGTGACTGAGGTI'CCTTG)  or JH4INR 
(5'-CAGGCTCCACCAGACCTCTCTAGA) (21). Control prim- 
ers  for  the  wild-type  TCR-ot  locus  have  been  described  else- 
where (20).  PCR products were cloned by the TA Cloning  |  Kit 
(Invitrogen, San Diego, CA) and sequenced by Sequenase  TM Ver- 
sion 2.0 (U.S. Biochemical Corp., Cleveland, OH). 
Antibody  Assays.  Serum IgM was determined by an ELISA Ig 
isotyping kit (Pierce Chemical Co., Rockford, IL); for inhibition, 
the serum equivalent of 100 I.tg IgM was preincubated with 1 mg 
total mouse IgG  (Southern)  at 37~  for  1 h.  Data reflect either 
lymphoma-free  or  lymphoma-afflicted T  cell-deficient lpr  ani- 
mals.  Serum  K rheumatoid  factor  was  determined as  described 
(22).  Statistical significance was evaluated by unpaired Student's 
t test. 
Results and Discussion 
T  cell-deficient, Fas-deficient animals developed intraab- 
dominal lymphoid malignancy with associated mortality at 
a  penetrance of at least 70%  (Figs.  1  and 2).  Affected mice 
possessed  severe  hepatosplenomegaly and malignant,  exu- 
dative  ascites  (Fig.  1  and  data  not  shown).  Such  animals 
Figure 1.  Representative autopsies of T cell-deficient  lpr mice. (A) An ot[3, ~  T cell-deficient lpr mouse with exudative hepatosplenomegaly caused 
by lymphoid malignancy. This animal contained a massively enlarged liver and spleen, the latter extending across the midline below the fight hepatic 
lobe. Autopsies were similar in lymphoma-attlicted ~x13, ~/~ T cell~deficient, Fas-intact mice, but hepatosplenomegaly and ascites were less prominent (not 
shown). Here, a moribund, 12 wk-old eq3, V~ T  cell-deficient  lpr mouse was killed and dissected, along with age-matched counterparts. The anterior 
peritoneum was removed to allow visualization of the peritoneal cavity. (B) Normal liver appearance, but splenomegaly and peripheral lymphadenopathy 
in a T cell-intact lpr mouse. Despite increased size, T cell-intact lpr spleens (left side of animal) had an appearance distinct from lymphoma-bearing eta, ~8 
T cell-deficient lpr spleens, which were of greater size and weight, and contained grossly visible exudates and/or fibrosis. Abdominal contents were simi- 
lar in "/8 T cell-deficient lpr animals (not shown). (C') Normal abdominal contents and lymph nodes in a T cell-intact, Fas-intact animal. Autopsy findings 
were similar in ot[3 T cell-deficient lpr and ~g T cell-deficient, Fas-intact mice (not shown), otJ3 T cell-deficient Fas-intact and lymphoma-free ot[3, "yB T 
cell-deficient animals possessed similar abdominal contents, but less prominent peripheral lymph nodes (not shown; 22). 
1150  lpr B Cell Lymphoma in T  Cell-deficient Mice Figure  2.  Histopathology  of  lpr-induced  lym- 
phoma. (A) High grade lymphoma infiltrating the liver 
of  an etJ3, ~/g T cell-deficient lprmouse  (bar =  67 p.m), 
which was also present in the kidney (B; bar, 100 p.m), 
periaortic lymph nodes (C; bar, 67 p,m), and spleen (D; 
bar, 100 p.m). (E) Mixed lymphocytic infiltrate in the 
kidney ofa T cell-intact lpr mouse (bar, 100 p.m), sim- 
ilar in morphology and constituency to the infdtrates in 
the liver of the same animal (not shown).  Similar le- 
sions were also found in ctJ3 T cell~teficient  lpr, ~  T 
cell-deficient  lpr, and some lymphoma-free  a/3, T/J T 
cell-deficient  animals (not  shown).  (F)  Infiltrate-free 
normal  liver  histology  in  a  T  cell-intact,  Fas-intact 
mouse  (bar, 200 p.m). Similarly normal histology was 
noted in otJ3 T cell-deficient Ipr, ~/~ T cell-deficient lpr, 
and most lymphoma-free ctJ3, ~/~ T cell-deficient ani- 
mals (not shown). 
generally possessed increased abdominal girth (25-30 cm at 
the umbilical line, vs.  15-20  cm for normal mice) because 
of malignant ascites accumulation (sometimes >10  ml) and 
abdominal organ enlargement. Notably, these  mice lacked 
lproinduced  peripheral  (e.g.,  inguinal,  axiUary)  lymphade- 
nopathy because of the absence of lpr T  cells (Fig. 1). Mice in 
this study varied in color because of their mixed genetic back- 
ground, which included both MIkL  (white)  and C57BL/6 
Figure 3.  Immunofluorescent characterization of lpr-induced B cell lymphoma. (A) Negative staining for CD3. Similarly negative were CD19, CD5, 
CD23, TCR_ [3, CD4, CD8, CD62L, IgG, IgD, MHC class I, NKI.1, Ly-49A, and Ly-49C (not shown). (/3) Positive staining of all infiltrating cells for 
IgM. Similarly positive were CD44, CD45RB, and B220 (not shown). Bar, 10 p.m. 
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Figure 4.  Natural  history  of lymphoma in T  cell~deficient lpr mice.  (/t) A vaJ558-J.4, but not a 
Vu7183-Ju4,  rearrangement  in livers containing  lymphoma  (livers 1 and  2). By contrast,  the T  cell- 
intact,  Fas-intact liver contained  no detectable  V(D)J rearrangements,  whereas the T  cell-intact,  Fas- 
intact spleen contained both rearrangements. A control amplification reaction using the TCR-o~ locus is 
shown.  Similarly, JH 1, JH2, and JH3 reverse primers failed to amplify products from T cell-intact Fas- 
intact  liver or from lymphomas,  but successfully amplified products  from the T  cell-intact,  Fas-intact 
spleen (not shown).  (B) Recovery of a single V(D)J rearrangement  from livers containing  tymphoma. 
By contrast,  multiple  clones were isolated from the T  cell-intact spleen.  Dashes indicate  nucleotide 
identity  at positions indicated.  (C) IgM titers in lymphoma-attlicted  (hatched  bar) vs. lymphoma-free, 
Fas-intact, and  lpr mice (open  bar). Elevated IgM in lymphoma-bearing  animals was caused by lgM, K 
rheumatoid  factor, since competitive mouse IgG inhibited  the majority ofIgM titers (C), and these an- 
imals contained  elevated K rheumatoid factor activity (D). (E) Incidence  of lethal lymphoma develop- 
ment in T cell-deficient lpr (thin solid line; n =  25) and Fas-intact mice (dashed line; n =  22). Lymphoma 
was not noted in other mouse groups containing  c~ and/or y8 T  cells (thick  solid  line;  n =  15-25  in 
each genotypic group). 
(black)  coat color genes; lymphoma  (as well as lack oflym- 
phoma)  was found among mice bearing either coat color. 
Histopathology  revealed invasion and infiltration by mi- 
totically  active  atypical  B  lymphocytes  (Fig.  2),  which 
stained  IgM+ IgD-IgG-B220+CD  19-CD5-CD23-CD3  - 
by immunofluorescence  (Fig. 3). Lymphoma cells possessed 
atypical but homogeneous  morphology,  numerous  mitotic 
figures,  and  large  nuclei indicative of an  aggressive,  malig- 
nant  process.  Lymphoid  organs,  including  the  liver,  were 
generally  80-90%  involved (not  shown).  In  contrast,  typi- 
1152  lpr B Cell Lymphoma in T  Cell-deficient Mice cal lpr-induced infiltrates in the liver and kidney were pleo- 
morphic  (Fig.  2  E)  and involved only 5-10%  of involved 
organs,  in  contrast  to  the  widespread  infiltration  seen  in 
lymphoma-bearing animals. 
PCR analysis of genomic DNA revealed that the lym- 
phomas were restricted to the expression of a V~558-JH4 
heavy  chain  rearrangement:  other  common  V(D)J  rear- 
rangements were not detected, including VH7183-JH 1, JH2, 
J.3, orJ.4, as well as vHj558-jH1, JH2, orJH3 (Fig. 4 A and 
data not shown).  Monoclonality was verified by sequence 
analysis  of PCR  products,  which  demonstrated  identical 
V(D)J rearrangements among several PCR. clones from the 
lymphoma,  but  variable  rearrangements  among  PCR 
clones from the wild-type spleen (Fig.  4  B).  The presence 
of an A---)G mutation among the clones in one lymphoma 
may  reflect  oligoclonality,  but  the  presence  of identical 
V-D and D-Jjoins of the same V, D, andJ regions strongly 
suggests that these sequences represent mutations within  a 
single clone caused by AmpliTaq error or perhaps somatic 
mutation (23).  These lymphomas secreted an IgM, K rheu- 
matoid factor,  as evidenced by severe elevations in  serum 
IgM  that  could  be  inhibited  by competitive  mouse  IgG 
(Fig.  4  C; P  <0.001),  as well as elevated serum K rheuma- 
toid factor (Fig. 4 D  and data not shown; P <0.001). 
Lethal lymphoma was  observed in  the  majority of oq3, 
y5 T  cell-deficient lpr mice  ("-'60-70% by 7  mo of age), 
but  was  partially penetrant  in  T  cell-deficient,  Fas-intact 
animals (,'-'10% by 7 mo of age; Figs.  1 and 4 E; P  <0.01). 
Tumors were not observed in mice containing either T  cell 
subtype,  regardless  of Fas  phenotype  (P  <0.001).  These 
findings were clearly demonstrated in o~[3 T  cell--deficient 
animals, which possessed a mean survival of more than 10 mo 
without lymphoma development (Figs. 2 and 4 E  and data 
not shown). T  cell-intact lpr and ~/g T  cell-deficient Ipr an- 
imals  demonstrated  increased  mortality compared to  Fas- 
intact counterparts which resulted from profound systemic 
autoimmunity  (unpublished  data),  but histological  exami- 
nation of the liver, spleen, lymph nodes, and kidneys from 
these mice failed to reveal subclinical lymphoma in 30-36- 
wk-old animals (Figs.  2 and 4 and data not shown).  Thus, 
mice containing  either cx]3 or ~/8  T  cells  were  capable of 
preventing the development oflymphoma. 
Accordingly,  these  findings  demonstrate  a  tumor  sup- 
pressor function for Fas and a regulatory role for el]3 and for 
",/8 T  cells  in  tumorigenesis.  Since  lymphoma  was  sup- 
pressed in Ipr animals containing  either T  cell but lacking 
functional Fas, these results strongly suggest that both types 
ofT cells may regulate B cell lymphoma via a Fas-indepen- 
dent mechanism. This may involve perforin or other Fas- 
independent  cytotoxic mechanisms  (19)  that are activated 
by MHC/peptide  complexes  (24)  or  nonpeptide  ligands 
(25).  Alternatively,  T  cells  may circumvent  the  need  for 
Fas-dependent regulation by inducing terminal differentia- 
tion,  as seen in  the  reduction  of myc-induced  lymphomas 
by the induction  of B  cell differentiation  (26).  Still,  Fas is 
directly implicated in the regulation of this lymphoma since 
T  cell-intact, Fas-intact animals developed malignancy at a 
significantly decreased penetrance compared to T  cell-defi- 
cient lpr counterparts.  Fas may affect tumorigenesis by in- 
teracting directly with  other  tumor  suppressor genes  like 
p53  (27),  or protooncogenes like bcl-2 (28).  These studies 
seem germane to the development of B  cell lymphoma in 
acquired immune deficiency syndrome, where chronic an- 
tigen stimulation may substitute for Fas deficiency in pro- 
moting a pool of premalignant B  cells that progress to ma- 
lignancy in the absence ofT cell regulation (29). 
We thank J. Moslehi for helpful discussion. 
This work was supported in part by grants from the National Institues of Health (AR40072 and AR44076 to 
J. Craft, and A138932 to A.C. Hayday) and from the Arthritis and Lupus Foundations, their Connecticut 
chapters, and donations to Yale Rheumatology in the memories of Irene Feltman, Albert L. Harlow, and 
Chantal Marquis (to J. Craft). SLP was supported by the Medical Scientist Training Program, Yale Univer- 
sity School of Medicine. 
Address correspondence to Joe Craft, M.D., Section of  Rheumatology, Yale University School of Medicine, 
P.O. Box 208031, LCI 609, 333 Cedar Street, New Haven, CT 06520-8031. 
Received for publication 12June  1996 and in revised  form 27June  1996. 
References 
1.  Nagata,  S., and P. Golstein.  1995. The Fas death factor. Sci- 
ence (Wash. DC). 267:1449-1456. 
2.  Singer,  G.G., and A.K. Abbas.  1994. The Fas antigen  is in- 
volved in peripheral  but not thymic deletion  of T  lympho- 
cytes in T cell receptor transgenic mice. Immunity. 1:365-371. 
3.  Fisher, G.H.,  F.J. Rosenberg,  S.E. Straus, J.K.  Dale,  L.A. 
Middleton,  A.Y.  Lin,  W.  Strober,  M.J.  Lenardo,  and J.M. 
Puck.  1995. Dominant interfering  Fas gene mutations impair 
apoptosis in a human autoimmune lymphoproliferative  syn- 
drome. Cell. 81:935-946. 
4.  Renno,  T., M.  Hahne, J.  Tschopp, and  H.R.  MacDonald. 
1996.  Peripheral  T  cells undergoing  superantigen-induced 
1153  Peng et al.  Brief Definitive Report apoptosis in vivo express B220  and upregulate Fas and  Fas 
ligand.J. Exp. Med.  183:431-437. 
5.  Van  Parijs,  L., A.  lbraghimov, and A.K. Abbas.  1996.  The 
roles of costimulation and Fas in T cell apoptosis and periph- 
eral tolerance. Immunity. 4:321-328. 
6.  Rathmell,  J.C.,  M.P.  Cooke,  W.Y.  Ho,  J.  Grein,  S.E. 
Townsend, M.M.  Davis, and C.C.  Goodnow.  1995.  CD95 
(Fas)-dependent elimination of self-reactive B  cells upon in- 
teraction with CD4 + T cells. Nature (Lond.).  376:181-184. 
7.  Rothstein,  T.L.,  J.K.  Wang,  D.J.  Panka,  L.C.  Foote,  Z. 
Wang, B.  Stanger, H.  Cui,  S.T. Ju,  and A. Marshak-Roth- 
stein. 1995.  Protection against Fas-dependent Thl-mediated 
apoptosis by antigen receptor engagement in B  cells. Nature 
(Lond.).  374:163-165. 
8.  Kondo,  E.,  T.  Yoshino,  I.  Yamadoti,  Y.  Matsuo,  N.  Ka- 
wasaki, J. Minowada, and T. Akagi.  1994. Expression  of Bcl-2 
protein and Fas antigen in non-Hodgkin's lymphomas. Am. 
J. Pathol.  145:330-337. 
9.  Lichter, P.,  H.  Walczak, S.  Weitz, I.  Behrmann,  and P.H. 
Krammer. 1992.  The human APO-1 (APT) antigen maps to 
10q23,  a region that is syntenic with mouse chromosome 19. 
Genomics.  14:179-180. 
10. Gray, I.C., S.M. Phillips, S.J. Lee, J.P. Neoptolemos, J. Weis- 
senbach, and N.K. Spurr. 1995.  Loss of the chromosomal re- 
gion 10q23-25 in prostate cancer. Cancer Res. 55:4800-4803. 
11. Simon, M., A. von Deimling, J.J.  Larson, R. Wellenreuther, 
P. Kaskel, A. Waha, R.E. Warnick, J.M. Tew, Jr., and A.G. 
Menon. 1995. Allelic losses on chromosomes 14, 10, and 1 in 
atypical  and  malignant  meningiomas:  a  genetic  model  of 
meningioma progression. Cancer Res. 55:4696-4701. 
12. Herbst, R.A., J. Weiss, A. Ehnis, W.K. Cavenee, and K.C. 
Arden. 1994. Loss of heterozygosity for 10q22-10qter in ma- 
lignant melanoma progression. Cancer Res. 54:3111-3114. 
13. Peiffer, S.L.,  T.J.  Herzog,  D.J.  Tribune,  D.G.  Mutch,  D.J. 
Gersell, and P.J.  Goodfellow. 1995.  Allelic loss of sequences 
from the long arm of chromosome 10 and replication errors 
in endometrial cancers. Cancer Res. 55:1922-1926. 
14. Speaks,  S.L., W.G. Sanger, A.S. Masih, D.S. Harrington, M. 
Hess,  and J.O.  Armitage.  1992.  Recurrent abnormalities of 
chromosome bands 10q23-25 in non-Hodgkin's lymphoma. 
Genes  Chrom.  Cancer. 5:239-243. 
15. Morse, H.C. Ili, W.F. Davidson, R.A. Yetter, E.D. Murphy, 
J.B. Roths, and R.L. Coffman. 1982.  Abnormalities induced 
by the mutant  gene  lpr: expansion of a unique lymphocyte 
subset.J. ImmunoI.  129:2612-2615. 
16. Senju, S., I. Negishi, N. Motoyama, F. Wang, K. Nakayama, 
K.  Nakayama,  P.J.  Lucas,  S.  Hatakeyama,  Q.  Zhang,  S. 
Yonehara, and D.Y. Loh. 1995. Functional significance of the 
Fas molecule in naive lymphocytes. Int. Immunol.  8:423-431. 
17. Morse, H.C. III, J.B. Roths, W.F. Davidson, W.Y. Langdon, 
T.N. Fredrickson, and J.W. Hartley. 1985. Abnomlalities in- 
duced by the mutant gene, lpr. Patterns of disease and expres- 
sion of murine leukemia viruses in SJL/J  mice homozygous 
and heterozygous for lpr. J. Exp. Med.  161:602-616. 
18. Andrews,  B.S.,  R.A.  Eisenberg,  A.N.  Theofilopoulos,  S. 
Izui,  C.B.  Wilson,  P.J.  McConahey,  E.D.  Murphy,  J.B. 
Roths, and F.J. Dixon. 1978.  Spontaneous murine lupus-like 
syndromes. Clinical and immunopathological manifestations 
in several strains.J. Exp. Med.  148:1198-1215. 
19. Roth, C., C. Rochlitz, and P. Kourilsky. 1994.  Imnmne re- 
sponse against tumors. Adv.  Immunol.  57:281-351. 
20.  Hughes, D.P.M., A. Hayday, J.E. Craft, M.J. Owen, and I.N. 
Crispe. 1995.  T cells with the y/8 T cell receptors (TCR) of 
intestinal type are preferentially expanded in  TCR-cc-defi- 
cient lpr mice.J. Exp. Med.  182:233-241. 
21. Retter, M.W., R.A. Eisenberg, P.L. Cohen, and S.H. Clarke. 
1995.  Sm and DNA binding by dual reactive B cells requires 
distinct V H, V K, and V H CDR3  structures. J.  Immunol.  155: 
2248-2257. 
22. Peng, S.L., M.P. Madaio, D.P.M. Hughes, I.N. Crispe, M.J. 
Owen, L. Wen, A.C. Hayday, andJ. Craft. 1996. Murine lu- 
pus in the absence of{x[~ T  cells.J. Immunol.  156:4041-4049. 
23.  Chu, Y.W., E. Matin, R. Fuleihan, N. Ramesh, F.S. Rosen, 
R.S.  Geha, and R.A.  Insel.  1995.  Somatic mutation of hu- 
man  immunoglobulin V  genes  in  the  X-linked HyperlgM 
syndrome.J. Clin. Invest.  95:1389-1393. 
24.  Ferrone, S., and F.M. Marincola.  1995.  Loss of HLA class I 
antigens  by  melanoma  cells:  molecular mechanisms,  func- 
tional significance and clinical relevance. Immunol.  Today.  16: 
487-494. 
25. Penninger, J.M., T. Wen, E. Timms, J. Potter, V.A. Wallace, 
T.  Matsuyama, D.  Fertick, B.  Sydora, M.  Kronenberg, and 
T.W. Mak. 1995.  Spontaneous resistance to acute T-cell leu- 
kaemias in TCRV',/1.1J~/4C',/4  transgenic mice. Nature (Lond.). 
375:241-244. 
26.  Nussenzweig,  M.C.,  E.V.  Schmidt, A.C.  Shaw,  E.  Sinn, J. 
Campos-Torres, B.  Mathey-Prevot, P.K. Pattengale, and P. 
Leder. 1988. A human immunoglobulin gene reduces the in- 
cidence oflymphomas in c-Myc-beating transgenic mice. Na- 
ture (Lond.).  336:446-450. 
27. Tamura,  T.,  N.  Aoyama, H.  Saya,  H.  Haga, S. Futami, M. 
Miyamoto, T.  Koh, T.  Ariyasu, M.  Tachi, and M.  Kasuga. 
1995.  Induction ofFas-mediated apoptosis in p53-transfected 
human colon carcinoma cells. Oncqqene.  11:1939-1946. 
28.  Chiou,  S.K.,  C.C.  Tseng,  L.  Rao,  and  E.  White.  1994. 
Functional complementation of the adenovirus E1B  19-kilo- 
dalton protein with Bcl-2 in the inhibition of apoptosis in in- 
fected cells.J.  Virol. 68:6553-6566. 
29. Monroe,  J.G.,  and  L.E.  Silberstein.  1995.  HIV-mediated 
B-lymphocyte activation and lymphomagenesis. J.  Clin.  Im- 
munol.  15:61-68. 
1154  lpr B Cell Lymphoma in T Cell-deficient Mice 